Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review

Brodalumab, a recombinant fully human monoclonal immunoglobulin IgG2 antibody with high affinity to human interleukin (IL)-17RA, is approved for the treatment of moderate-to-severe plaque psoriasis. In controlled clinical trials, brodalumab 210 mg administered by subcutaneous injection at weeks 0, 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinter, Andreas, Bonnekoh, Bernd, Hadshiew, Ina Marion, Zimmer, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628099/
https://www.ncbi.nlm.nih.gov/pubmed/31372022
http://dx.doi.org/10.2147/CCID.S211938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628099/
https://www.ncbi.nlm.nih.gov/pubmed/31372022
http://dx.doi.org/10.2147/CCID.S211938

Ejemplares similares